7 Hot Drug Stocks To Buy In 2020
Jan 3, 2020 11:16:41 GMT -5
alethea, sportsrancho, and 20 more like this
Post by harryx1 on Jan 3, 2020 11:16:41 GMT -5
7 Hot Drug Stocks To Buy In 2020
www.forbes.com/sites/moneyshow/2020/01/03/7-hot-drug-stocks-to-buy-in-2020/
Nate Pile, Nate's Notes
MannKind (MNKD) has a proprietary drug delivery platform called Technosphere that allows it to deliver a wide variety of drugs to the body through the lungs rather than via pills or injections (thus allowing for an often much faster onset of action).
The company's lead product is Afrezza (inhalable insulin), and it is already approved by the FDA for use by both type 1 and type 2 diabetics. Though still quite small relative other mealtime insulins, sales of Afrezza have been growing steadily for the past couple of years,
Doctors need to see results in a small group of patients before they'll start expanding use of the new therapy into the rest of their practice, and the reality is that this "trial" period often takes 12-18 months when it comes to managing diabetes.
And, given the manner in which new ways of managing diabetes have been adopted in the past, I believe the odds are good that 2020 will be the year that Afrezza finally starts to gain some meaningful traction in the marketplace.
Along with Afrezza, MannKind is also developing a Technosphere-based version of treprostinil (along with another undisclosed molecule) with its partner United Therapeutics (UTHR). It also has an agreement in place with privately-held Receptor Life Sciences (RLS) under which RLS is developing cannabis-based products utilizing the Technosphere platform.
And though they are not yet licensed to partners, MannKind is also working on inhalable versions of a number of interesting compounds, most notably epinephrine (for anaphylactic shock), sumatriptan (migraines), and tadalafil (erectile dysfunction).
Thanks to a very aggressive group of short sellers who have flooded the market with 40 million "extra" shares over the years, MannKind's market cap has been beaten down just over half of what it was when the company first came public back in 2004. While it remains to be seen how things will actually play I do find it encouraging that all of those short sales represent pent up buying demand when short sellers eventually close out their trades.
www.forbes.com/sites/moneyshow/2020/01/03/7-hot-drug-stocks-to-buy-in-2020/
Nate Pile, Nate's Notes
MannKind (MNKD) has a proprietary drug delivery platform called Technosphere that allows it to deliver a wide variety of drugs to the body through the lungs rather than via pills or injections (thus allowing for an often much faster onset of action).
The company's lead product is Afrezza (inhalable insulin), and it is already approved by the FDA for use by both type 1 and type 2 diabetics. Though still quite small relative other mealtime insulins, sales of Afrezza have been growing steadily for the past couple of years,
Doctors need to see results in a small group of patients before they'll start expanding use of the new therapy into the rest of their practice, and the reality is that this "trial" period often takes 12-18 months when it comes to managing diabetes.
And, given the manner in which new ways of managing diabetes have been adopted in the past, I believe the odds are good that 2020 will be the year that Afrezza finally starts to gain some meaningful traction in the marketplace.
Along with Afrezza, MannKind is also developing a Technosphere-based version of treprostinil (along with another undisclosed molecule) with its partner United Therapeutics (UTHR). It also has an agreement in place with privately-held Receptor Life Sciences (RLS) under which RLS is developing cannabis-based products utilizing the Technosphere platform.
And though they are not yet licensed to partners, MannKind is also working on inhalable versions of a number of interesting compounds, most notably epinephrine (for anaphylactic shock), sumatriptan (migraines), and tadalafil (erectile dysfunction).
Thanks to a very aggressive group of short sellers who have flooded the market with 40 million "extra" shares over the years, MannKind's market cap has been beaten down just over half of what it was when the company first came public back in 2004. While it remains to be seen how things will actually play I do find it encouraging that all of those short sales represent pent up buying demand when short sellers eventually close out their trades.
Hmmm ... I wonder who predicted it this way?